

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA - Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (managed access review of TA620) [ID3788]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| Not applicable |

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No potential equality issues have been raised in the submissions, expert statements or academic report. |

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No other potential equality issue have been identified by the committee. |

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
None identified

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
None identified

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
None identified

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
None were identified, so it is not discussed in the FAD.

Approved by Associate Director (name):Janet Robertson.....

Date: 26 May 2023